Prostate cancer growth is almost wholly dependent on the route of the
androgen receptor and most
therapies aimed at blocking this signaling axis are useful tools in the management of this
disease. Unfortunately such
therapies invariably fail, and the
cancer progresses to an
androgen-independent stage. In such cases,
androgen receptor mutation almost always occurs and much evidence suggests the continuous
growth of the
tumor. One mechanism by which the receptor is
thought to remain active is
mutation. This
paper reviews the molecular mechanism of
tumor growing after
androgen receptor mutation and some of the promising management principles and systemic
chemotherapy options against
prostate cancer.